GlaxoSmithKline Pharmaceuticals Limited
GLAXO
Rankning i aktier
#3669
GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise,... GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise, engages in the research, development, production, and global distribution of pharmaceutical drugs and vaccines. Its extensive product range encompasses both prescription and over-the-counter medications addressing diverse therapeutic areas such as anti-infectives, respiratory ailments, dermatology, nutritional deficiencies, gastrointestinal issues, and rare conditions. The company additionally provides consumer healthcare solutions. Prominent brands within its portfolio include Augmentin, Calpol, Ceftum, Eltroxin, Neosporin, Betnovate, Infanrix Hexa, Synflorix, and Boostrix, among numerous others. Founded in 1924 and headquartered in Mumbai, India, the company adopted its current name in 2001, having previously operated as SmithKline Beecham Pharmaceuticals India Ltd.
Aktiekurs
$27.17
Marknadsvärde
$4.60B
Förändring (1 dag)
-1.33%
Förändring (1 år)
-13.30%
Land
IN
Handel GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
Kategori
Healthcare
Antal utestående aktier för GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
Antal utestående aktier per June 2026: 169.41M
Enligt de senaste finansiella rapporterna och aktiekursen för GlaxoSmithKline Pharmaceuticals Limited är det aktuella antalet utestående aktier 169.41M. I slutet av March 2024 hade företaget 169.41M utestående aktier. Antalet utestående aktier påverkas vanligtvis av aktiesplit och återköp av aktier.
Historik över utestående aktier för GlaxoSmithKline Pharmaceuticals Limited (GLAXO) från 2004 till 2026
Utestående aktier vid slutet av varje år
| År | Utestående aktier | Ändra |
|---|---|---|
| 2026 (TTM) | 169.41M | 0.00% |
| 2025 | 169.41M | 0.00% |
| 2024 | 169.41M | -0.50% |
| 2023 | 170.26M | -4.88% |
| 2022 | 178.98M | 5.65% |
| 2021 | 169.41M | 0.00% |
| 2020 | 169.41M | 0.00% |
| 2019 | 169.41M | 0.00% |
| 2018 | 169.41M | 0.00% |
| 2017 | 169.41M | 0.00% |
| 2016 | 169.41M | 0.00% |
| 2015 | 169.41M | 0.00% |
| 2013 | 169.41M | 0.00% |
| 2012 | 169.41M | 0.00% |
| 2011 | 169.41M | 0.00% |
| 2010 | 169.41M | 0.00% |
| 2009 | 169.41M | 0.00% |
| 2008 | 169.41M | 0.00% |
| 2007 | 169.41M | 0.00% |
| 2006 | 169.41M | -1.29% |
| 2005 | 171.62M | -1.73% |
| 2004 | 174.65M | 0.00% |
Utestående aktier för liknande företag eller konkurrenter
| Företag | Utestående aktier | Skillnad | Land |
|---|---|---|---|
| 892.40M | 426.78% |
US
|
|
| 2.45B | 1,344.78% |
US
|
|
| 1.77B | 945.41% |
US
|
|
| 0.00 | -100.00% |
US
|
|
| 796.00M | 369.88% |
CH
|
